Undisclosed obesity therapeutic / Onconic Therapeutics - LARVOL DELTA

Onconic Therapeutics unveils OCN-501 to preserve muscle with GLP-1 therapy (Chosun Biz) - "Onconic Therapeutics said on the 12th that The Obesity Society in the United States disclosed the title of an oral abstract on the latest research related to OCN-501 through its annual meeting, ObesityWeek...Specific methods and results will be released at the conference to be held in Washington in November....OCN-501 focuses on securing additional therapeutic effects, such as muscle preservation, through combination therapy rather than competing on weight-loss efficacy with existing GLP-1 class treatments. Onconic Therapeutics plans to develop it as a first-in-class drug candidate."

New molecule • Preclinical • Obesity